Welcome to the Treating CD30+ Lymphoma Platform

Welcome, this website is intended for healthcare professionals with an interest in the treatment of lymphoma. By clicking the link below you are declaring and confirming that you are a healthcare professional.

Welcome to the Treating CD30+ Lymphomas Webcast Platform

These webcast modules aim to provide education for physicians on the approved brentuximab vedotin data within the licensed indications, and are available to view as separate education modules.

The expert faculty, Dr. Anna Sureda and Dr. Martin Hutchings will cover: an introduction to brentuximab vedotin, mode of action, the Phase I and II clinical data for HL and sALCL and the recently released long term survival analysis. Modules also include transplant ineligible patients and safety updates.

Brentuximab vedotin was approved by the European Medicines Agency (EMA) in October 2012.

See here for full indication.

Share

E-alert

Subscribe to our E-Alert to keep up to date with new webcast content published to the site.

Sponsor

This multimedia activity has been sponsored by Takeda Oncology.

Note that Takeda Oncology has no editorial control over the content of this multimedia activity. The multimedia activity and all content therein has been subject to an independent editorial review.